Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease

Melanoma Research

Volumn 15, Issue 1, 2005, Pages 53-60

  Alonso, Rebeca ^a   Suarez, Ana ^a   Castro, Patricia ^b   Lacave, Angel J ^a,b   Gutierrez, Carmen ^a,b  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Gender; Genetic polymorphism; Interleukin 10; Malignant melanoma; Overall survival; Recurrence

Indexed keywords

INTERLEUKIN 10;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-10; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); SKIN NEOPLASMS; SURVIVAL RATE;

EID: 14844350948     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200502000-00009     Document Type: Article

References (42)

1. Kaskel P, Berking C, Sanders S, Volkenandt M, Peter RU, Krahn G. S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma. J Am Acad Dermatol 1999; 41:962-969.
2. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19:577-583.
3. Cuba M, Steinbauer M, Ruhland V, Schutz A, Geissler EK, Anthuber M, et al. Elevated mia serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. Oncol Rep 2002; 9:981-984.
4. Chen Q, Daniel V, Maher DW, Mersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56:755-760.
5. Krüger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Hüls C, Blankestein T, et al. Expression of interleukin 10 in human melanoma. Br J Cancer 1994; 70:1182-1185.
6. Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D, Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 1995; 41:151-156.
7. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, et al. Interleukin 10 production by human melanoma. Clin Cancer Res 1996; 2:1383-1390.
8. Dummer W, Becker JC, Schwaaf A, Leverkus M, Molt T, Broker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995; 5:67-68.
9. Boyano MD, Garcia-Vázquez MD, López-Michelena T, Gardeazabal J, Bilbao J, Cañavate ML, et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 2000; 83:847-852.
10. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001; 19:239-247.
11. Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 1996; 157:231-238.
12. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 suppresses tumour growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 1996; 2:1969-1979.
13. Landáyi A, Nagy JO, Jeney A, Timar J. Cytokine sensitivity of metastatic human melanoma cell lines - simultaneous inhibition of proliferation and enhancement of gelatinase activity. Pathol Oncol Res 1998; 2:108-114.
14. Westendorp RGJ, Langermans JAM, Huizinga TWJ, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349:170-173.
15. Eskdale J, Gallager G, Verweij CL, Keijsers V, Westendorp RGJ. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95:9465-9470.
16. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24:1-8.
17. Hajeer AH, Lazarus M, Turner D, Mageed RA, Vencovsky J, Sinnot P, et al. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol 1998; 27:142-145.
18. Suarez A, Castro P, Alonso R, Mozo L, Gutiérrez C. Inter-individual variations on constitutive IL-10 mRNA and protein levels and their association with genetic polymorphisms. Transplantation 2003; 75:711-717.
19. Leach-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004; 103:3529-3534.
20. Breen EC, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O'Brien SJ, et al. Non-Hodgkin's B lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter 592 C/C genotype. Clin Immunol 2003; 109:119-129.
21. Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJ. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44:251-255.
22. Zheng C, Huang D, Liu L, Wu R, Bergenbrant Glas S, Osteeborg A, et al. Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer 2001; 95:184-188.
23. Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, Lin JT. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 2003; 104:617-623.
24. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62:3369-3372.
25. Roh JW, Kim MH, Seo SS, Kim SH, Kim JW, Park NH, et al. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett 2002; 184:57-63.
26. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001; 2:25-31.
27. Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernández-Caselles T, Frias JF, et al. Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 2002; 12:465-469.
28. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
29. Johnson VJ, Yucesoy B, Luster MI. Genotyping of single nucleotide polymorphisms in cytokine genes using real-time PCR allelic discrimination technology. Cytokine 2004; 27:135-141.
30. Schröder J, Kahlke V, Staubach H, Zabel P, Stüber F. Gender differences in human sepsis. Arch Surg 1998; 133:1200-1205.
31. Liva SM, Voskuhl RR. Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol 2001; 167:2060-2067.
32. Angele MK, Knoferl MW, Ayala A, Bland KL, Chaudry IH. Testosterone and estrogen differently affect Th1 and Th2 cytokine release following trauma-haemorrhage. Cytokine 2001; 16:22-30.
33. Väisänen A, Kallionen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of mmp-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998; 186:51-58.
34. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001; 19:3622-3634.
35. Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis. Clin Cancer Res 1999; 5:189-196.
36. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 1999; 19:697-703.
37. Gerard CM, Bruyns C, Delvaux A, Baudson N, Dargent JL, Goldman M, et al. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther 1996; 7:23-31.
38. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184:579-584.
39. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Soirg C. Macrophages and angiogenesis. J Leukocyte Biol 1994; 55:410-422.
40. Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson JL, et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 2000; 96:2568-2573.
41. Mtairag EM, Chollet-Martin S, Oudghiri M, Laquay N, Jacob MP, Michel JB, et al. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovascular Res 2001; 49:882-890.
42. Richter G, Kruger-Krasagakes S, Hein G, Huls C, Schmitt E, Diamanstein T, et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993; 53:4134-4137.